Cytokinetics Updates Phase 3 COURAGE-ALS Trial of Reldesemtiv

Cytokinetics Updates Phase 3 COURAGE-ALS Trial of Reldesemtiv

314158

Cytokinetics Updates Phase 3 COURAGE-ALS Trial of Reldesemtiv

Most of the initial amyotrophic lateral sclerosis (ALS) patients enrolled in Cytokinetics’ COURAGE-ALS Phase 3 trial testing its experimental therapy reldesemtiv have moderate-to-fast progressing disease at study entry. An analysis shows that, as intended, COURAGE-ALS is increasing the proportion of patients with rapidly progressing disease compared with the recently completed FORTITUDE-ALS Phase 2 trial (NCT03160898). “The analysis of patients enrolled to date in COURAGE-ALS shows that the great majority of patients have middle and fast…

You must be logged in to read/download the full post.